That included Sanofi and Regeneron’s rival PCSK9 inhibitor Praluent (alirocumab), which reached the US market shortly after Repatha in 2015. The ruling could effectively put an end to attempts ...

Currently available PCSK9-targeting therapies are Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab), both antibodies dosed monthly, and Novartis' small interfering RNA ...

The first PCSK9 inhibitor to receive FDA approval was the Praluent injection by Sanofi in July 2015. Since then, other PCSK9 inhibitors have made it to market, such as the injection Repatha by Amgen.

The Phase III PACMAN-AMI trial (NCT03067844) investigated the effect of Regeneron Pharmaceutials’ PCSK9 inhibitor Praluent ...